CDKN2A and triple-negative breast carcinoma: Of all ER/PR/ERBB2 triple-negative breast cancer patients, 7.5% possessed whole-gene deletions of CDKN2A, encoding the p16INK4a competitive inhibitor of Cdk4 [39].